Cargando…

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review

SIMPLE SUMMARY: Hematological malignancies are diseases involving the abnormal production of blood cells. The aim of the study is to collect comprehensive information on new drugs used in the treatment of blood cancers which have introduced into therapy in the last decade. The approved drugs were an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sochacka-Ćwikła, Aleksandra, Mączyński, Marcin, Regiec, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750348/ https://www.ncbi.nlm.nih.gov/pubmed/35008250 http://dx.doi.org/10.3390/cancers14010087

Ejemplares similares

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2022)

New Oxazolo[5,4-d]pyrimidines as Potential Anticancer Agents: Their Design, Synthesis, and In Vitro Biological Activity Research
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2022)

Synthesis, Physicochemical Characteristics and Plausible Mechanism of Action of an Immunosuppressive Isoxazolo[5,4-e]-1,2,4-Triazepine Derivative (RM33)
por: Mączyński, Marcin, et al.
Publicado: (2021)

Synthesis and Biological Activity of New 7-Amino-oxazolo[5,4-d]Pyrimidine Derivatives
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2020)

Trends in FDA drug approvals over last 2 decades: An observational study
por: Batta, Angelika, et al.
Publicado: (2020)

FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade
por: Idrees, Zarwa, et al.
Publicado: (2022)

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment
por: Ho, Cheryl, et al.
Publicado: (2022)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Current FDA-Approved Therapies for High-Grade Malignant Gliomas
por: Fisher, Jacob P., et al.
Publicado: (2021)

Cyclic peptide drugs approved in the last two decades (2001–2021)
por: Zhang, Huiya, et al.
Publicado: (2021)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
por: Rizzo, Carla, et al.
Publicado: (2023)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
por: Shabir, Ghulam, et al.
Publicado: (2023)

Synthesis and clinical application of new drugs approved by FDA in 2022
por: Zhang, Jing-Yi, et al.
Publicado: (2023)

A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects
por: Shi, Zhenfeng, et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
por: Tompa, Dharma Rao, et al.
Publicado: (2021)

Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
por: Martins, Alexander C., et al.
Publicado: (2022)

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
por: Nishikawa, Shigeto, et al.
Publicado: (2023)

Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
por: Varadharajan, Ashvin, et al.
Publicado: (2023)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
por: Nunes, Débora, et al.
Publicado: (2022)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs
por: Ismail, Magda M. F., et al.
Publicado: (2022)

A review of FDA approved drugs and their formulations for the treatment of breast cancer
por: Chaurasia, Mohini, et al.
Publicado: (2023)

Antibody–Drug Conjugates: The Last Decade
por: Joubert, Nicolas, et al.
Publicado: (2020)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2021)

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2018)

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: G. de la Torre, Beatriz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8c56jcci2pm0fm648qp5pkq8hg